Skip to main content
Top
Published in: Diabetologia 10/2009

01-10-2009 | Article

Effects of glucokinase activators GKA50 and LY2121260 on proliferation and apoptosis in pancreatic INS-1 beta cells

Authors: P. Wei, M. Shi, S. Barnum, H. Cho, T. Carlson, J. D. Fraser

Published in: Diabetologia | Issue 10/2009

Login to get access

Abstract

Aims/hypothesis

Glucokinase (GK), an enzyme that phosphorylates glucose to form glucose 6-phosphate, serves as the glucose sensor that regulates insulin secretion in beta cells. GK activators (GKAs) activate GK via binding to an allosteric site of the enzyme. GKAs increase glucose-stimulated insulin secretion and decrease blood glucose levels. Using the differentiated beta cell line INS-1, we investigated the role of GKAs in promoting beta cell growth and survival and preventing beta cell apoptosis induced by chronic exposure to high levels of glucose.

Methods

Proliferation was assessed using BrdU incorporation. Apoptosis was measured using caspase-3 activity. Immunoblot analysis was used to detect protein levels and the degree of phosphorylation.

Results

The GK agonists GKA50 and LY2121260 increased both cell replication and cell numbers when tested at basal levels of glucose (3 mmol/l) in INS-1 cells. GKAs promoted INS-1 cell proliferation via upregulation of insulin receptor substrate-2 and subsequent activation of protein kinase B phosphorylation. GKA50 also prevented the INS-1 cell apoptosis that was induced by chronic high glucose conditions, probably via an increase in GK protein levels and normalisation of the apoptotic protein BCL2-associated agonist of cell death (BAD) and its phosphorylation. As a result of the reduction in cell apoptosis, GKA50 prevented cell loss and maintained glucose-stimulated insulin secretion. In addition, the anti-apoptotic activity of GKA50 was significantly abrogated by other GKAs that do not inhibit apoptosis, suggesting that direct binding of GKA50 to GK is essential for its anti-apoptotic effect.

Conclusion/interpretation

Our results suggest novel roles of GKAs in promoting beta cell growth and preventing chronic-hyperglycaemia-induced beta cell apoptosis. Thus, GKAs may provide novel therapeutics that increase beta cell mass to maintain euglycaemia in diabetes.
Literature
1.
go back to reference Butler AE, Janson J, Soeller WC, Butler PC (2003) Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes 52:2304–2314PubMedCrossRef Butler AE, Janson J, Soeller WC, Butler PC (2003) Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes 52:2304–2314PubMedCrossRef
2.
3.
go back to reference Matschinsky FM, Ellerman JE (1968) Metabolism of glucose in the islets of Langerhans. J Biol Chem 243:2730–2736PubMed Matschinsky FM, Ellerman JE (1968) Metabolism of glucose in the islets of Langerhans. J Biol Chem 243:2730–2736PubMed
4.
go back to reference Matschinsky FM (2002) Regulation of pancreatic beta-cell glucokinase: from basics to therapeutics. Diabetes 51(Suppl 3):S394–404PubMedCrossRef Matschinsky FM (2002) Regulation of pancreatic beta-cell glucokinase: from basics to therapeutics. Diabetes 51(Suppl 3):S394–404PubMedCrossRef
5.
go back to reference Tsakiris D, Ioannou K (2004) An underdiagnosed type of diabetes: the MODY syndromes. Pathophysiology, clinical presentation and renal disease progression. J Nephrol 17:637–641PubMed Tsakiris D, Ioannou K (2004) An underdiagnosed type of diabetes: the MODY syndromes. Pathophysiology, clinical presentation and renal disease progression. J Nephrol 17:637–641PubMed
6.
go back to reference Grimsby J, Sarabu R, Corbett WL et al (2003) Allosteric activators of glucokinase: potential role in diabetes therapy. Science 301:370–373PubMedCrossRef Grimsby J, Sarabu R, Corbett WL et al (2003) Allosteric activators of glucokinase: potential role in diabetes therapy. Science 301:370–373PubMedCrossRef
7.
go back to reference Terauchi Y, Takamoto I, Kubota N et al (2007) Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. J Clin Invest 117:246–257PubMedCrossRef Terauchi Y, Takamoto I, Kubota N et al (2007) Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. J Clin Invest 117:246–257PubMedCrossRef
9.
go back to reference Danial NN, Gramm CF, Scorrano L et al (2003) BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 424:952–956PubMedCrossRef Danial NN, Gramm CF, Scorrano L et al (2003) BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 424:952–956PubMedCrossRef
10.
go back to reference Kim WH, Lee JW, Suh YH et al (2005) Exposure to chronic high glucose induces beta-cell apoptosis through decreased interaction of glucokinase with mitochondria: downregulation of glucokinase in pancreatic beta-cells. Diabetes 54:2602–2611PubMedCrossRef Kim WH, Lee JW, Suh YH et al (2005) Exposure to chronic high glucose induces beta-cell apoptosis through decreased interaction of glucokinase with mitochondria: downregulation of glucokinase in pancreatic beta-cells. Diabetes 54:2602–2611PubMedCrossRef
11.
go back to reference Heredia VV, Thomson J, Nettleton D, Sun S (2006) Glucose-induced conformational changes in glucokinase mediate allosteric regulation: transient kinetic analysis. Biochemistry 45:7553–7562PubMedCrossRef Heredia VV, Thomson J, Nettleton D, Sun S (2006) Glucose-induced conformational changes in glucokinase mediate allosteric regulation: transient kinetic analysis. Biochemistry 45:7553–7562PubMedCrossRef
12.
go back to reference Wang Q, Li L, Xu E, Wong V, Rhodes C, Brubaker PL (2004) Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia 47:478–487PubMedCrossRef Wang Q, Li L, Xu E, Wong V, Rhodes C, Brubaker PL (2004) Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia 47:478–487PubMedCrossRef
13.
go back to reference Brocklehurst KJ, Payne VA, Davies RA et al (2004) Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators. Diabetes 53:535–541PubMedCrossRef Brocklehurst KJ, Payne VA, Davies RA et al (2004) Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators. Diabetes 53:535–541PubMedCrossRef
14.
go back to reference McKerrecher D, Allen JV, Caulkett PW et al (2006) Design of a potent, soluble glucokinase activator with excellent in vivo efficacy. Bioorg Med Chem Lett 16:2705–2709PubMedCrossRef McKerrecher D, Allen JV, Caulkett PW et al (2006) Design of a potent, soluble glucokinase activator with excellent in vivo efficacy. Bioorg Med Chem Lett 16:2705–2709PubMedCrossRef
15.
go back to reference Efanov AM, Barrett DG, Brenner MB et al (2005) A novel glucokinase activator modulates pancreatic islet and hepatocyte function. Endocrinology 146:3696–3701PubMedCrossRef Efanov AM, Barrett DG, Brenner MB et al (2005) A novel glucokinase activator modulates pancreatic islet and hepatocyte function. Endocrinology 146:3696–3701PubMedCrossRef
16.
go back to reference Kamata K, Mitsuya M, Nishimura T, Eiki J, Nagata Y (2004) Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure 12:429–438PubMedCrossRef Kamata K, Mitsuya M, Nishimura T, Eiki J, Nagata Y (2004) Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure 12:429–438PubMedCrossRef
17.
go back to reference Lingohr MK, Briaud I, Dickson LM et al (2006) Specific regulation of IRS-2 expression by glucose in rat primary pancreatic islet beta-cells. J Biol Chem 281:15884–15892PubMedCrossRef Lingohr MK, Briaud I, Dickson LM et al (2006) Specific regulation of IRS-2 expression by glucose in rat primary pancreatic islet beta-cells. J Biol Chem 281:15884–15892PubMedCrossRef
18.
go back to reference Leighton B, Atkinson A, Coghlan MP (2005) Small molecule glucokinase activators as novel anti-diabetic agents. Biochem Soc Trans 33:371–374PubMedCrossRef Leighton B, Atkinson A, Coghlan MP (2005) Small molecule glucokinase activators as novel anti-diabetic agents. Biochem Soc Trans 33:371–374PubMedCrossRef
19.
go back to reference Sarabu R, Grimsby J (2005) Targeting glucokinase activation for the treatment of type 2 diabetes—a status review. Curr Opin Drug Discov Dev 8:631–637 Sarabu R, Grimsby J (2005) Targeting glucokinase activation for the treatment of type 2 diabetes—a status review. Curr Opin Drug Discov Dev 8:631–637
20.
go back to reference Matschinsky FM, Magnuson MA, Zelent D et al (2006) The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes 55:1–12PubMedCrossRef Matschinsky FM, Magnuson MA, Zelent D et al (2006) The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes 55:1–12PubMedCrossRef
21.
go back to reference Gorman T, Hope DC, Brownlie R et al (2008) Effect of high-fat diet on glucose homeostasis and gene expression in glucokinase knockout mice. Diabetes Obes Metab 10:885–897PubMedCrossRef Gorman T, Hope DC, Brownlie R et al (2008) Effect of high-fat diet on glucose homeostasis and gene expression in glucokinase knockout mice. Diabetes Obes Metab 10:885–897PubMedCrossRef
22.
go back to reference Cousin SP, Hugl SR, Myers MG Jr, White MF, Reifel-Miller A, Rhodes CJ (1999) Stimulation of pancreatic beta-cell proliferation by growth hormone is glucose-dependent: signal transduction via janus kinase 2 (JAK2)/signal transducer and activator of transcription 5 (STAT5) with no crosstalk to insulin receptor substrate-mediated mitogenic signalling. Biochem J 344:649–658PubMedCrossRef Cousin SP, Hugl SR, Myers MG Jr, White MF, Reifel-Miller A, Rhodes CJ (1999) Stimulation of pancreatic beta-cell proliferation by growth hormone is glucose-dependent: signal transduction via janus kinase 2 (JAK2)/signal transducer and activator of transcription 5 (STAT5) with no crosstalk to insulin receptor substrate-mediated mitogenic signalling. Biochem J 344:649–658PubMedCrossRef
23.
go back to reference Ashcroft SJ (1980) Glucoreceptor mechanisms and the control of insulin release and biosynthesis. Diabetologia 18:5–15PubMedCrossRef Ashcroft SJ (1980) Glucoreceptor mechanisms and the control of insulin release and biosynthesis. Diabetologia 18:5–15PubMedCrossRef
24.
go back to reference Withers DJ, Gutierrez JS, Towery H et al (1998) Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391:900–904PubMedCrossRef Withers DJ, Gutierrez JS, Towery H et al (1998) Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391:900–904PubMedCrossRef
25.
go back to reference Kubota N, Tobe K, Terauchi Y et al (2000) Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. Diabetes 49:1880–1889PubMedCrossRef Kubota N, Tobe K, Terauchi Y et al (2000) Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. Diabetes 49:1880–1889PubMedCrossRef
26.
go back to reference Srinivasan S, Bernal-Mizrachi E, Ohsugi M, Permutt MA (2002) Glucose promotes pancreatic islet beta-cell survival through a PI 3-kinase/Akt-signaling pathway. Am J Physiol 283:E784–793 Srinivasan S, Bernal-Mizrachi E, Ohsugi M, Permutt MA (2002) Glucose promotes pancreatic islet beta-cell survival through a PI 3-kinase/Akt-signaling pathway. Am J Physiol 283:E784–793
27.
go back to reference Johnson D, Shepherd RM, Gill D, Gorman T, Smith DM, Dunne MJ (2007) Glucose-dependent modulation of insulin secretion and intracellular calcium ions by GKA50—a glucokinase activator. Diabetes 56:1694–1702PubMedCrossRef Johnson D, Shepherd RM, Gill D, Gorman T, Smith DM, Dunne MJ (2007) Glucose-dependent modulation of insulin secretion and intracellular calcium ions by GKA50—a glucokinase activator. Diabetes 56:1694–1702PubMedCrossRef
28.
go back to reference Park S, Dong X, Fisher TL et al (2006) Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. J Biol Chem 281:1159–1168PubMedCrossRef Park S, Dong X, Fisher TL et al (2006) Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. J Biol Chem 281:1159–1168PubMedCrossRef
29.
go back to reference Weir GC, Bonner-Weir S (2007) A dominant role for glucose in beta cell compensation of insulin resistance. J Clin Invest 117:81–83PubMedCrossRef Weir GC, Bonner-Weir S (2007) A dominant role for glucose in beta cell compensation of insulin resistance. J Clin Invest 117:81–83PubMedCrossRef
30.
go back to reference Kaiser N, Leibowitz G, Nesher R (2003) Glucotoxicity and beta-cell failure in type 2 diabetes mellitus. J Pediatr Endocrinol Metab 16:5–22PubMed Kaiser N, Leibowitz G, Nesher R (2003) Glucotoxicity and beta-cell failure in type 2 diabetes mellitus. J Pediatr Endocrinol Metab 16:5–22PubMed
31.
go back to reference Pick A, Clark J, Kubstrup C et al (1998) Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 47:358–364PubMedCrossRef Pick A, Clark J, Kubstrup C et al (1998) Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 47:358–364PubMedCrossRef
32.
go back to reference Donath MY, Gross DJ, Cerasi E, Kaiser N (1999) Hyperglycaemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. Diabetes 48:738–744PubMedCrossRef Donath MY, Gross DJ, Cerasi E, Kaiser N (1999) Hyperglycaemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. Diabetes 48:738–744PubMedCrossRef
33.
go back to reference Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N (2001) Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 15:1406–1418PubMedCrossRef Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N (2001) Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 15:1406–1418PubMedCrossRef
Metadata
Title
Effects of glucokinase activators GKA50 and LY2121260 on proliferation and apoptosis in pancreatic INS-1 beta cells
Authors
P. Wei
M. Shi
S. Barnum
H. Cho
T. Carlson
J. D. Fraser
Publication date
01-10-2009
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1446-0

Other articles of this Issue 10/2009

Diabetologia 10/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine